| |
Recently, translational research, which serves to pass on the “seeds” obtained through basic and clinical studies to clinical practice, has been promoted as a national policy; not surprisingly this has stimulated collaboration among industry, academia, and the government. In these circumstances, it has become increasingly difficult to draw a line between basic and clinical research. As a basic concept, even if a particular business-academic collaboration research project is basic and clinical (for example, preclinical tests, analysis of human blood and biological samples), it is desirable to disclose its COI with relevant companies if the outcome of the research may influence clinical practice (prevention, diagnostics, treatment, and other methods) and may be related to the interests of companies or other for-profit organizations that sponsor the research. This is because, in a case where suspicion has been raised in relation to the outcome of an industry-academia collaborative clinical study, having a proper prior declaration of COI, the Japan Osteoporosis Society can establish its accountability from the standpoint of the researchers concerned. |
